Tumour markers are substances found in your blood, tissue, or other body fluids that may signal the presence of cancer. Your body produces them either directly from cancer cells or as a response from healthy tissue surrounding a tumour. Understanding what tumour markers are, how doctors use them, and what your results might mean can help you feel more informed and less anxious during cancer care. This article explains everything you need to know in plain language.
What Are Tumour Markers?
A tumour marker is a substance — usually a protein — that appears in higher-than-normal amounts when cancer is present. Cancer cells themselves can produce these substances. In other cases, the body’s healthy cells produce them in reaction to a nearby tumour.
Doctors can detect tumour markers in blood samples, urine, or tumour tissue. However, finding a tumour marker does not always mean a person has cancer. Some non-cancerous conditions can also raise these levels. That is why doctors never rely on tumour markers alone to diagnose cancer.
According to the World Health Organization’s cancer fact sheet, early and accurate detection of cancer remains one of the most important factors in improving survival rates worldwide.
How Do Tumour Markers Work?
Each type of tumour marker is linked to a specific type of cancer or a small group of cancers. For example, a marker called PSA (prostate-specific antigen) is associated with prostate cancer. Another marker, CA-125, is often linked to ovarian cancer.
When a doctor orders a tumour marker test, they take a blood sample and send it to a laboratory. The lab measures the level of the specific marker in your blood. Your doctor then compares that result to the normal range.
A single elevated result rarely tells the whole story. Therefore, doctors usually order repeat tests over time. They look for trends — is the marker level rising, falling, or staying stable? These trends are often more meaningful than any single result.
Common Examples of Tumour Markers
There are many different tumour markers, and researchers continue to discover new ones. Here are some of the most commonly used ones in Canadian clinical practice:
PSA (Prostate-Specific Antigen): Used to monitor prostate cancer.
CA-125: Often associated with ovarian cancer.
CA 19-9: Linked to pancreatic and gastrointestinal cancers.
CEA (Carcinoembryonic Antigen): Associated with colorectal cancer and several others.
AFP (Alpha-Fetoprotein): Used to monitor liver cancer and certain testicular cancers.
Calcitonin: A key marker for medullary thyroid cancer, especially in families with a known history of the condition.
HER2: Found in some breast cancer tumours and used to guide treatment decisions.
Your doctor will choose which tumour marker test is appropriate based on your symptoms, medical history, and the type of cancer being investigated or monitored.
How Doctors Use Tumour Markers in Cancer Care
Tumour markers serve several important purposes throughout the cancer care journey. They are rarely used for just one reason. Instead, they support a broader picture of your health alongside imaging tests, biopsies, and physical examinations.
Monitoring Cancer Progression
One of the most valuable uses of tumour markers is tracking how a cancer is behaving over time. If a marker level rises steadily, it may suggest the cancer is growing or spreading. If the level drops, it could mean the cancer is responding well to treatment.
For example, a person undergoing chemotherapy for colorectal cancer might have their CEA levels checked regularly. A falling CEA level is an encouraging sign. A rising level may prompt the doctor to reconsider the current treatment plan.
Evaluating Treatment Effectiveness
Tumour markers also help doctors measure how well a treatment is working. This is particularly useful between imaging scans, which are not always done frequently. Blood tests for tumour markers can give your care team a quicker, less invasive update on your progress.
Furthermore, some cancer treatments — including targeted therapies — are specifically designed to act on tumour markers. For instance, certain breast cancer drugs target the HER2 protein directly. In these cases, the tumour marker is not just a monitoring tool. It is also the target of the treatment itself.
Detecting Cancer Recurrence
After a person finishes cancer treatment, tumour markers play an important role in follow-up care. Doctors may monitor marker levels during regular check-ups to watch for signs that cancer has returned. A rising marker level after a period of remission can be an early warning sign, often appearing before symptoms develop or before a tumour is visible on a scan.
This kind of early detection during follow-up is one of the most clinically valuable uses of tumour markers in Canadian oncology practice.
Can Tumour Markers Be Used for Early Cancer Detection?
Many people wonder whether tumour marker tests can be used to screen healthy individuals for cancer before any symptoms appear. The honest answer is: in most cases, no — at least not on their own.
The main challenge is that many tumour markers are not specific enough. Several non-cancerous conditions — such as infections, inflammation, or benign growths — can also raise marker levels. This can lead to false positives, causing unnecessary worry and additional testing.
However, there are a few important exceptions. Tumour markers do have a role in early detection for certain cancers that run in families. Medullary thyroid cancer is a clear example. People with a family history of this condition may be tested for calcitonin or for genetic mutations that raise their risk. In these specific cases, tumour marker testing as part of a broader screening plan can genuinely save lives.
The Mayo Clinic’s overview of tumour marker tests provides a helpful summary of which markers are currently used in screening versus monitoring contexts.
The Importance of Not Self-Diagnosing
It can be tempting to search for tumour marker tests online or at private labs without first speaking to a doctor. However, this approach carries real risks. Without the right clinical context, a result — whether high or normal — can be deeply misleading.
Always speak with your family doctor before seeking any cancer-related testing. They can help you decide whether a test is appropriate and what the results actually mean for your specific situation.
Tumour Markers and New Cancer Treatments
Beyond monitoring and detection, tumour markers are opening exciting new doors in cancer treatment. Researchers are actively studying how these markers can be used as direct targets for therapy.
One promising area involves monoclonal antibodies — lab-made proteins designed to attach to specific tumour markers on cancer cells. Once attached, these antibodies can flag cancer cells for destruction by the immune system or deliver cancer-killing drugs directly to the tumour.
In addition, a growing class of drugs called targeted therapies works by interfering with the specific molecules — often tumour markers — that help cancer cells grow and survive. These treatments tend to cause fewer side effects than traditional chemotherapy because they focus on cancer cells rather than attacking all rapidly dividing cells in the body.
Canada’s cancer research community, including institutions supported by the Canadian Cancer Society, is actively involved in clinical trials exploring these therapeutic approaches. As a result, Canadians with certain cancer types may have access to innovative treatments through their provincial cancer programmes.
Tumour Markers and the Canadian Healthcare System
In Canada, tumour marker tests are typically ordered by a specialist — such as an oncologist — or by your family doctor when there is clinical reason to do so. Most tumour marker blood tests are covered under provincial health plans when ordered for medically appropriate reasons.
However, coverage policies vary by province and territory. For example, routine PSA screening in asymptomatic men without risk factors is not universally recommended or covered across all provinces. Your family doctor can explain what is covered under your provincial health plan and what the current guidelines recommend for your age and risk profile.
If you do not have a family doctor, a walk-in clinic is a good place to start. The physician there can assess your concerns, order appropriate tests if needed, and refer you to a specialist if necessary. You can also check with your provincial health authority for guidance on accessing cancer screening services in your area.
For more information on cancer care resources available to Canadians, visit Health Canada’s official health information portal.
When to See a Doctor About Tumour Markers
You should speak with your family doctor if you have concerns about cancer risk, especially if there is a history of cancer in your immediate family. Some cancers — like medullary thyroid cancer — have a clear hereditary component, and early testing can make a significant difference.
You should also talk to your doctor if you are currently undergoing cancer treatment and want to understand what your tumour marker results mean. Do not try to interpret results on your own. The numbers only make sense in the full context of your health history and treatment plan.
If you notice unusual symptoms — such as unexplained weight loss, persistent fatigue, unusual lumps, or changes in bowel or bladder habits — book an appointment with your family doctor as soon as possible. A walk-in clinic is also a reasonable option if your regular doctor is not immediately available.
Remember: tumour marker tests are a tool that doctors use as part of a larger assessment. They are not a definitive answer on their own. Always rely on a qualified healthcare provider to guide your care.
Frequently Asked Questions About Tumour Markers
What are tumour markers used for?
Tumour markers are primarily used to monitor the progression of cancer and evaluate how well treatment is working. They can also help doctors detect whether cancer has returned after treatment. In a few specific cases, tumour markers support early detection in people with a family history of certain cancers.
Can a tumour marker test diagnose cancer?
No, a tumour marker test alone cannot diagnose cancer. Elevated tumour marker levels can also be caused by non-cancerous conditions such as infections or inflammation. Doctors always combine tumour marker results with other tests — such as imaging and biopsies — before making a diagnosis.
Are tumour marker tests covered by provincial health plans in Canada?
In most cases, tumour marker tests are covered by provincial health plans when ordered by a doctor for a medically appropriate reason. However, coverage can vary depending on your province and the specific test being requested. Speak with your family doctor to find out what is covered under your provincial plan.
What does it mean if my tumour marker level is high?
A high tumour marker level does not automatically mean you have cancer or that your cancer is getting worse. Many factors can affect these levels, including other health conditions and even certain medications. Your doctor will review the result in the context of your overall health before drawing any conclusions.
Which cancers have the most reliable tumour markers?
Some of the most well-established tumour markers include PSA for prostate cancer, CA-125 for ovarian cancer, CEA for colorectal cancer, and calcitonin for medullary thyroid cancer. However, even these markers are most useful for monitoring rather than initial diagnosis. Your oncologist or family doctor can tell you which markers are relevant to your situation.
How often should tumour marker levels be checked?
The frequency of tumour marker testing depends on the type of cancer, the stage of treatment, and your doctor’s clinical judgement. During active treatment, tests may be done every few weeks. During follow-up after remission, they might be done every few months or annually. Your care team will create a monitoring schedule that is right for you.
Key Takeaways
Tumour markers are substances in the blood or tissue that may signal cancer activity in the body.
They are produced either by cancer cells directly or by healthy cells reacting to a tumour.
Their primary use is to monitor cancer progression and measure how well treatment is working.
Tumour markers also help detect cancer recurrence during follow-up care after treatment.
They are not reliable as standalone screening tools for the general population, with a few specific exceptions such as medullary thyroid cancer in families with a known history.
Exciting new cancer treatments — including targeted therapies and monoclonal antibodies — use tumour markers as direct therapeutic targets.
In Canada, these tests are usually covered by provincial health plans when ordered for an appropriate medical reason.
Always consult your family doctor or walk-in clinic if you have concerns about cancer risk or want to understand your test results.
Never interpret tumour marker results on your own — context and professional guidance are essential.
